BMY Bristol-Myers Squibb
Stock · NYSE · United States · Healthcare · US1101221083
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Bristol-Myers Squibb, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
62.47 USD
-1.05%
52-week range
62.47
Low45.27High68.64
Dividend yield3.99%
Market cap129.0B
NowoTrade score
70 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 16:28. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 18 Jan 2022 – 21 Jan 2022 | 64.68 | 65.35 | 63.29 | 63.54 | -2.14% | 47,666,900 | |
| 10 Jan 2022 – 14 Jan 2022 | 62.80 | 65.85 | 62.76 | 64.93 | +3.34% | 69,185,600 | |
| 03 Jan 2022 – 07 Jan 2022 | 62.07 | 63.27 | 60.86 | 62.83 | +0.77% | 59,567,600 | 0.5400 |
| 27 Dec 2021 – 31 Dec 2021 | 62.09 | 63.17 | 61.77 | 62.35 | +0.48% | 33,114,400 | |
| 20 Dec 2021 – 23 Dec 2021 | 61.44 | 62.56 | 60.88 | 62.05 | +0.80% | 42,760,700 | |
| 13 Dec 2021 – 17 Dec 2021 | 57.26 | 62.67 | 57.11 | 61.56 | +9.23% | 101,022,800 | |
| 06 Dec 2021 – 10 Dec 2021 | 56.52 | 57.88 | 56.11 | 56.36 | +0.07% | 71,507,400 | |
| 29 Nov 2021 – 03 Dec 2021 | 55.84 | 56.69 | 53.22 | 56.32 | -0.37% | 103,269,900 | |
| 22 Nov 2021 – 26 Nov 2021 | 57.81 | 58.32 | 55.82 | 56.53 | -2.25% | 62,167,200 | |
| 15 Nov 2021 – 19 Nov 2021 | 59.80 | 60.06 | 57.80 | 57.83 | -2.69% | 55,884,200 | |
| 08 Nov 2021 – 12 Nov 2021 | 59.80 | 60.20 | 58.76 | 59.43 | -0.03% | 47,855,200 | |
| 01 Nov 2021 – 05 Nov 2021 | 58.30 | 59.86 | 58.29 | 59.45 | — | 59,441,300 |
Page 11 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
Key data
- Previous close
- 63.13 USD
- Market cap
- 129.0B
- Dividend yield
- 3.99%
- 5-year average yield
- 3.86%
- Payout ratio
- 56%
- Last dividend
- 0.6300 USD · 02 Oct 2026
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 02 Oct 2026 | 0.6300 USD |
| 02 Jul 2026 | 0.6300 USD |
| 02 Apr 2026 | 0.6300 USD |
| 02 Jan 2026 | 0.6300 USD |
| 03 Oct 2025 | 0.6200 USD |
| 03 Jul 2025 | 0.6200 USD |
| 04 Apr 2025 | 0.6200 USD |
| 03 Jan 2025 | 0.6200 USD |
| 04 Oct 2024 | 0.6000 USD |
| 05 Jul 2024 | 0.6000 USD |
| 04 Apr 2024 | 0.6000 USD |
| 04 Jan 2024 | 0.6000 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 16.6 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 23.1 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 7.4 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 10.0 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 9.1 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 2.2 / 5 |
|
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| P/E (trailing)Price divided by the last 12 months of earnings per share: how many years of profit you pay for. Lower is cheaper. | 14.07× | Good | 32.71× | Good up to 15× · fair up to 25× |
| P/E (forward)The same, with the profit analysts expect for the next 12 months. | 9.54× | Good | 15.76× | Good up to 15× · fair up to 25× |
| Price / bookPrice against the accounting value of what the company owns minus what it owes. | 5.54× | Weak | 3.74× | Good up to 1.5× · fair up to 3× |
| Price / salesPrice against yearly revenue; useful when there is no profit yet. | 2.59× | Fair | 3.52× | Good up to 2× · fair up to 5× |
| EV / EBITDAWhat the whole business costs (shares plus net debt) against its operating earnings. | 8.96× | Good | 13.54× | Good up to 10× · fair up to 15× |
| Free cash flow yieldThe cash left after investments, as a share of the market value. | 4.9% | Fair | 3% | Good from 5% · fair from 2% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Gross marginWhat is left of each sale after the direct cost of what was sold. | 70.5% | Good | 66.1% | Good from 40% · fair from 20% |
| Operating marginWhat is left of each sale after all operating costs. | 33.8% | Good | 8% | Good from 15% · fair from 8% |
| Net marginWhat is left of each sale after everything, tax included. | 18.5% | Good | 3.5% | Good from 10% · fair from 5% |
| Return on equityProfit for each euro the shareholders have invested. | 44% | Good | 6.4% | Good from 15% · fair from 8% |
| Return on assetsProfit for each euro of the company's assets. | 10.9% | Good | 3.9% | Good from 7% · fair from 3% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Revenue growth / yearYearly growth of revenue over the years we have figures for. | 1.4% | Weak | 10.5% | Good from 8% · fair from 3% |
| EPS growth / yearYearly growth of earnings per share over the same years. | 5.5% | Fair | 7% | Good from 8% · fair from 3% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Debt / equityHow much the company owes for each euro of its own capital. | 1.91× | Weak | 0.52× | Good up to 0.8× · fair up to 1.6× |
| Net debt / EBITDAYears of operating earnings needed to pay the debt off (negative: more cash than debt). | 1.77× | Fair | 1.62× | Good up to 1.5× · fair up to 3× |
| Interest coverHow many times the operating profit covers the interest on the debt. | 7.26× | Fair | 3.3× | Good from 8× · fair from 3× |
| Current ratioShort-term assets against short-term debts: above 1 it can pay what is due this year. | 1.59× | Good | 2.12× | Good from 1.5× · fair from 1× |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Payout of earningsThe share of the profit paid out as dividend. Under 100% it is covered by earnings. | 55.9% | Fair | 0% | Good up to 50% · fair up to 70% |
| Payout of free cash flowThe share of the free cash flow paid out as dividend; cash, not accounting profit, pays dividends. | 79.3% | Weak | 45% | Good up to 50% · fair up to 70% |
| Payout of free cash flow (3 years)The same, averaged over three years so one odd year does not mislead. | 37.2% | Good | — | Good up to 50% · fair up to 70% |
| Dividend growth / yearYearly growth of the dividend per share. | 4.7% | Fair | 7.1% | Good from 5% · fair from 2% |
| Years of rising dividendsConsecutive years in which the dividend went up. | 4 | Fair | 4.5 | Good from 10 · fair from 3 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BMY and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.